HRP20120066T1 - Kalijeva sol inhibitora hiv integraze - Google Patents
Kalijeva sol inhibitora hiv integraze Download PDFInfo
- Publication number
- HRP20120066T1 HRP20120066T1 HR20120066T HRP20120066T HRP20120066T1 HR P20120066 T1 HRP20120066 T1 HR P20120066T1 HR 20120066 T HR20120066 T HR 20120066T HR P20120066 T HRP20120066 T HR P20120066T HR P20120066 T1 HRP20120066 T1 HR P20120066T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- treatment
- prophylaxis
- monopotassium salt
- salt
- Prior art date
Links
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 title claims 3
- 239000003112 inhibitor Substances 0.000 title 1
- 229940126062 Compound A Drugs 0.000 claims abstract 9
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims abstract 9
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract 3
- 229910052802 copper Inorganic materials 0.000 claims abstract 3
- 239000010949 copper Substances 0.000 claims abstract 3
- 230000005855 radiation Effects 0.000 claims abstract 3
- 238000011282 treatment Methods 0.000 claims 5
- 238000011321 prophylaxis Methods 0.000 claims 4
- 208000030507 AIDS Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 238000002441 X-ray diffraction Methods 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63313204P | 2004-12-03 | 2004-12-03 | |
| PCT/US2005/043728 WO2006060712A2 (fr) | 2004-12-03 | 2005-12-02 | Sel de potassium d'un inhibiteur de l'integrase du vih |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120066T1 true HRP20120066T1 (hr) | 2012-03-31 |
Family
ID=36171569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120066T HRP20120066T1 (hr) | 2004-12-03 | 2012-01-23 | Kalijeva sol inhibitora hiv integraze |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US7754731B2 (fr) |
| EP (2) | EP1819700B1 (fr) |
| JP (1) | JP4705956B2 (fr) |
| KR (2) | KR101350420B1 (fr) |
| CN (1) | CN101068793B (fr) |
| AR (2) | AR052034A1 (fr) |
| AT (2) | ATE518844T1 (fr) |
| AU (1) | AU2005311671B8 (fr) |
| BR (1) | BRPI0518760A8 (fr) |
| CA (1) | CA2588398C (fr) |
| CR (1) | CR9146A (fr) |
| CY (1) | CY1112859T1 (fr) |
| DK (1) | DK1819700T3 (fr) |
| EA (1) | EA012418B1 (fr) |
| ES (2) | ES2370136T3 (fr) |
| GE (1) | GEP20105086B (fr) |
| HK (1) | HK1115011A1 (fr) |
| HR (1) | HRP20120066T1 (fr) |
| IL (1) | IL183614A (fr) |
| MA (1) | MA29120B1 (fr) |
| ME (1) | ME01985B (fr) |
| MX (1) | MX2007006639A (fr) |
| MY (1) | MY144320A (fr) |
| NI (1) | NI200700138A (fr) |
| NO (1) | NO338784B1 (fr) |
| NZ (1) | NZ555376A (fr) |
| PE (1) | PE20061148A1 (fr) |
| PL (1) | PL1819700T3 (fr) |
| PT (1) | PT1819700E (fr) |
| RS (1) | RS52197B (fr) |
| SI (1) | SI1819700T1 (fr) |
| TN (1) | TNSN07215A1 (fr) |
| TW (1) | TWI344463B (fr) |
| UA (1) | UA87884C2 (fr) |
| WO (2) | WO2006060712A2 (fr) |
| ZA (1) | ZA200704130B (fr) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4856623B2 (ja) | 2004-03-11 | 2012-01-18 | フォーエスシー アクチエンゲゼルシャフト | 新規のｎ−スルホニルピロール誘導体 |
| CN101068533B (zh) * | 2004-12-03 | 2011-04-27 | 默沙东公司 | 含有抗成核剂的药物组合物 |
| EP1904067B2 (fr) * | 2004-12-03 | 2017-10-11 | Merck Sharp & Dohme Corp. | Formulation pharmaceutique de derives de carboxamide , inhibiteurs de l'hiv integrase, comprenant une composition a liberation contrôlee |
| JP2008521934A (ja) * | 2004-12-03 | 2008-06-26 | メルク エンド カムパニー インコーポレーテッド | Ｕｇｔ１ａ１によって代謝される薬物の薬物動態を改善するためのアタザナビルの使用 |
| BRPI0708470A2 (pt) * | 2006-03-14 | 2011-05-31 | Merck & Co Inc | processo para a produção de partìculas cristalinas de um composto ativo orgánico, e, composição farmacêutica |
| EP2046328A4 (fr) | 2006-07-19 | 2009-10-28 | Univ Georgia Res Found | Dicétoacides de pyridinone : inhibiteurs de la réplication du vih dans une thérapie combinée |
| WO2009009531A2 (fr) * | 2007-07-09 | 2009-01-15 | Concert Pharmaceuticals Inc. | Nouveaux dérivés de pyrimidinecarboxamide |
| CA2710987A1 (fr) * | 2008-01-08 | 2009-07-16 | Merck Sharp & Dohme Corp. | Procede de preparation d'hydroxypyrimidinone carboxamides n-substitues |
| EP2438062B1 (fr) * | 2009-06-02 | 2015-07-29 | Hetero Research Foundation | Procédé de préparation de potassium de raltégravir amorphe |
| WO2011024192A2 (fr) | 2009-07-27 | 2011-03-03 | Matrix Laboratories Ltd | Nouveaux polymorphes du raltegravir |
| CA2777937C (fr) * | 2009-10-26 | 2017-08-29 | Merck Sharp & Dohme Corp. | Compositions pharmaceutiques solides contenant un inhibiteur d'integrase |
| DE102009056636A1 (de) | 2009-12-02 | 2011-06-09 | Ratiopharm Gmbh | Raltegravir-Polymorphe |
| KR20120094098A (ko) * | 2009-12-07 | 2012-08-23 | 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 | 피리디논 하이드록시사이클로펜틸 카복사미드: 치료 용도의 ｈｉｖ 인테그라제 억제제 |
| ES2362598B1 (es) * | 2009-12-17 | 2012-06-13 | Consejo Superior De Investigaciones Científicas (Csic) | Uso del raltegravir y derivados para la elaboración de medicamentos destinados al tratamiento de infecciones por herpesvirus. |
| US20130079360A1 (en) * | 2010-04-01 | 2013-03-28 | Ana KWOKAL | Raltegravir salts and crystalline forms thereof |
| US8987272B2 (en) * | 2010-04-01 | 2015-03-24 | Critical Outcome Technologies Inc. | Compounds and method for treatment of HIV |
| EP2575465A4 (fr) * | 2010-05-25 | 2013-11-20 | Hetero Research Foundation | Sels de raltégravir |
| WO2012009446A1 (fr) | 2010-07-16 | 2012-01-19 | Concert Pharmaceuticals Inc. | Nouveaux dérivés pyrimidinecarboxamide |
| CN101914067B (zh) * | 2010-08-26 | 2012-07-11 | 陈岱岭 | N-甲基嘧啶酮的合成方法 |
| JO3209B1 (ar) * | 2010-11-05 | 2018-03-08 | H Lundbeck As | طريقة لتصنيع نالتريكسون |
| WO2012103105A1 (fr) | 2011-01-24 | 2012-08-02 | Assia Chemical Industries Ltd. | Procédés de préparation du raltégravir et de ses intermédiaires dans lesdits procédés |
| WO2012106534A2 (fr) * | 2011-02-02 | 2012-08-09 | The Regents Of The University Of California | Inhibiteurs de l'intégrase du vih |
| EP2694497A1 (fr) | 2011-04-06 | 2014-02-12 | Lupin Limited | Nouveaux sels de raltégravir |
| JP2014512386A (ja) * | 2011-04-22 | 2014-05-22 | メルク・シャープ・アンド・ドーム・コーポレーション | 味がマスクされたラルテグラビル製剤 |
| US9968607B2 (en) | 2011-04-25 | 2018-05-15 | Hetero Research Foundation | Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof |
| EP2522665A1 (fr) | 2011-05-03 | 2012-11-14 | Sandoz Ag | Sel de sodium cristallin d'un inhibiteur de l'intégrase du VIH |
| EP2529741B1 (fr) | 2011-06-01 | 2014-02-12 | Ratiopharm GmbH | Composition et comprimé comprenant raltégravir |
| WO2013037731A1 (fr) | 2011-09-16 | 2013-03-21 | Hexal Ag | Nouvelle forme polymorphe du raltégravir potassium |
| CN103130787B (zh) * | 2011-11-24 | 2015-06-10 | 南开大学 | 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性 |
| CN103130788B (zh) * | 2011-11-24 | 2015-09-02 | 南开大学 | 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性 |
| US9403809B2 (en) | 2011-12-26 | 2016-08-02 | Emcure Pharmaceuticals Limited | Synthesis of raltegravir |
| WO2013111100A1 (fr) | 2012-01-25 | 2013-08-01 | Lupin Limited | Prémélange de potassium de raltégravir amorphe et stable, et procédé de préparation associé |
| WO2014064711A2 (fr) * | 2012-10-22 | 2014-05-01 | Hetero Research Foundation | Procédés d'administration de raltégravir et de compositions de raltégravir |
| EP2818470A1 (fr) | 2013-06-27 | 2014-12-31 | Basf Se | Co-cristeaux de raltégravir potassium |
| US9856270B2 (en) | 2013-07-17 | 2018-01-02 | Ratiopharm Gmbh | Dolutegravir salts |
| WO2015114608A1 (fr) | 2014-02-03 | 2015-08-06 | Mylan Laboratories Ltd | Procédés pour la préparation d'intermédiaires de raltégravir |
| CA2942239C (fr) * | 2014-03-21 | 2020-09-22 | Mylan Laboratories Ltd. | Premelange de sel de potassium de raltegravir cristallin et procede de preparation associe |
| US10257840B2 (en) | 2014-10-22 | 2019-04-09 | Telefonaktiebolaget Lm Ericsson (Publ) | Operation of wireless local area network in the presence of periodic interference |
| US10259778B2 (en) | 2014-11-10 | 2019-04-16 | Aurobindo Pharma Ltd | Process for the preparation of raltegravir |
| EP3472134B1 (fr) * | 2016-06-21 | 2021-10-20 | Pharmathen S.A. | Procédé de préparation de composés utilisés comme intermédiaires pour la préparation du raltégravir |
| WO2018051239A1 (fr) | 2016-09-15 | 2018-03-22 | Lupin Limited | Procédé de préparation de la forme 3 du potassium de raltégravir cristalline pure et stable |
| CN108610338A (zh) * | 2016-12-12 | 2018-10-02 | 天津国际生物医药联合研究院 | 一种嘧啶酮酰胺类化合物的制备方法 |
| HRP20220613T1 (hr) | 2017-11-14 | 2022-06-24 | Cambrex Profarmaco Milano S.R.L. | Postupak priprave raltegavira |
| US20210290548A1 (en) * | 2018-06-06 | 2021-09-23 | Merck Sharp & Dohme Corp. | Formulations of raltegravir |
| GB201907305D0 (en) * | 2019-05-23 | 2019-07-10 | Douglas Pharmaceuticals Ltd | Treatment of conditions |
| WO2021148992A1 (fr) | 2020-01-23 | 2021-07-29 | Lupin Limited | Compositions pharmaceutiques de raltégravir |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH624391A5 (fr) * | 1976-12-14 | 1981-07-31 | Ciba Geigy Ag | |
| US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5717097A (en) * | 1991-11-08 | 1998-02-10 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| IL121789A (en) * | 1996-10-03 | 2001-06-14 | Rohm & Haas | A medicinal product for inhibiting mammalian cell tumors |
| KR20010089708A (ko) * | 1998-12-25 | 2001-10-08 | 시오노 요시히코 | Ｈｉｖ 인테그라제 저해 활성을 갖는 방향족 복소환 유도체 |
| IT1318424B1 (it) * | 2000-03-24 | 2003-08-25 | Unihart Corp | Composti con attivita' anti-hiv. |
| EA200300449A1 (ru) | 2000-10-12 | 2003-10-30 | Мерк Энд Ко., Инк. | Аза- и полиаза-нафталинилкарбоксамиды, полезные в качестве ингибиторов вич-интегразы |
| GB0028483D0 (en) * | 2000-11-22 | 2001-01-10 | Hoffmann La Roche | Hydroxyethylamine HIV protease inhibitors |
| MXPA04003932A (es) * | 2001-10-26 | 2004-06-18 | Angeletti P Ist Richerche Bio | Inhibidores de la hidroxipirimidinona carboxamida n-sustituida de la integrasa del virus de inmunodeficiencia humana. |
| US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| EP1465889B1 (fr) * | 2001-12-21 | 2017-03-22 | Genzyme Corporation | Composes heterocycliques a efficacite accrue se fixant sur les recepteurs de la chimiokine |
| DE60329318D1 (de) * | 2002-11-20 | 2009-10-29 | Japan Tobacco Inc | 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren |
| EP1578748B1 (fr) * | 2002-12-27 | 2010-09-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Tetrahydro-4h-pyrido[1,2-a]pyrimidines et composes connexes convenant comme inhibiteurs de l'integrase du vih |
| TW200423930A (en) * | 2003-02-18 | 2004-11-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitors |
| CN101068533B (zh) | 2004-12-03 | 2011-04-27 | 默沙东公司 | 含有抗成核剂的药物组合物 |
| JP2008521934A (ja) | 2004-12-03 | 2008-06-26 | メルク エンド カムパニー インコーポレーテッド | Ｕｇｔ１ａ１によって代謝される薬物の薬物動態を改善するためのアタザナビルの使用 |
| EP1904067B2 (fr) | 2004-12-03 | 2017-10-11 | Merck Sharp & Dohme Corp. | Formulation pharmaceutique de derives de carboxamide , inhibiteurs de l'hiv integrase, comprenant une composition a liberation contrôlee |
-
2005
- 2005-02-12 UA UAA200707372A patent/UA87884C2/uk unknown
- 2005-11-24 AR ARP050104911A patent/AR052034A1/es not_active Application Discontinuation
- 2005-11-25 TW TW094141625A patent/TWI344463B/zh active
- 2005-11-25 MY MYPI20055516A patent/MY144320A/en unknown
- 2005-12-01 PE PE2005001398A patent/PE20061148A1/es not_active Application Discontinuation
- 2005-12-02 PL PL05852840T patent/PL1819700T3/pl unknown
- 2005-12-02 ES ES05852866T patent/ES2370136T3/es active Active
- 2005-12-02 ME MEP-2012-21A patent/ME01985B/fr unknown
- 2005-12-02 BR BRPI0518760A patent/BRPI0518760A8/pt not_active Application Discontinuation
- 2005-12-02 RS RS20120021A patent/RS52197B/en unknown
- 2005-12-02 EP EP05852840A patent/EP1819700B1/fr active Active
- 2005-12-02 US US11/293,678 patent/US7754731B2/en active Active
- 2005-12-02 WO PCT/US2005/043728 patent/WO2006060712A2/fr active Application Filing
- 2005-12-02 PT PT05852840T patent/PT1819700E/pt unknown
- 2005-12-02 ES ES05852840T patent/ES2375788T3/es active Active
- 2005-12-02 CA CA2588398A patent/CA2588398C/fr active Active
- 2005-12-02 AT AT05852866T patent/ATE518844T1/de active
- 2005-12-02 EP EP05852866A patent/EP1819683B1/fr active Active
- 2005-12-02 KR KR1020077015278A patent/KR101350420B1/ko active IP Right Grant
- 2005-12-02 MX MX2007006639A patent/MX2007006639A/es active IP Right Grant
- 2005-12-02 KR KR1020137028450A patent/KR20130122031A/ko not_active Application Discontinuation
- 2005-12-02 CN CN2005800416393A patent/CN101068793B/zh active Active
- 2005-12-02 JP JP2007544570A patent/JP4705956B2/ja active Active
- 2005-12-02 GE GEAP200510157A patent/GEP20105086B/en unknown
- 2005-12-02 SI SI200531435T patent/SI1819700T1/sl unknown
- 2005-12-02 DK DK05852840.7T patent/DK1819700T3/da active
- 2005-12-02 WO PCT/US2005/043781 patent/WO2006060730A2/fr active Application Filing
- 2005-12-02 AT AT05852840T patent/ATE534645T1/de active
- 2005-12-02 AU AU2005311671A patent/AU2005311671B8/en active Active
- 2005-12-02 NZ NZ555376A patent/NZ555376A/en unknown
- 2005-12-02 EA EA200701204A patent/EA012418B1/ru not_active IP Right Cessation
-
2007
- 2007-05-22 ZA ZA200704130A patent/ZA200704130B/xx unknown
- 2007-05-23 CR CR9146A patent/CR9146A/es not_active Application Discontinuation
- 2007-05-28 NI NI200700138A patent/NI200700138A/es unknown
- 2007-05-31 IL IL183614A patent/IL183614A/en active IP Right Grant
- 2007-06-01 TN TNP2007000215A patent/TNSN07215A1/fr unknown
- 2007-06-29 MA MA30041A patent/MA29120B1/fr unknown
- 2007-07-02 NO NO20073404A patent/NO338784B1/no unknown
-
2008
- 2008-04-29 HK HK08104747.0A patent/HK1115011A1/xx unknown
-
2010
- 2010-06-04 US US12/793,801 patent/US8357798B2/en active Active
-
2012
- 2012-01-23 HR HR20120066T patent/HRP20120066T1/hr unknown
- 2012-02-21 CY CY20121100173T patent/CY1112859T1/el unknown
-
2014
- 2014-04-24 AR ARP140101707A patent/AR101429A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120066T1 (hr) | Kalijeva sol inhibitora hiv integraze | |
| RU2014110399A (ru) | Кристаллические формы вгс протеазного ингибитора | |
| MX2022007372A (es) | Compuestos de heteroarilo sustituidos utiles como activadores de celulas t. | |
| NZ742200A (en) | Treatment of osteoarthritis | |
| MX2022007842A (es) | Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t. | |
| TW200736258A (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| HRP20160208T4 (hr) | Polimorfi dasatiniba i postupak za njihovu pripremu | |
| MY139399A (en) | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist | |
| HRP20140666T1 (hr) | Kristalni oblici derivata 2-tiazolil-4-kinolinil-oksi, snažnog hcv-inhibitora | |
| ES2613716T3 (es) | Formas cristalinas de un derivado de purina | |
| RU2012146517A (ru) | Соли ральтегравира и их кристаллические формы | |
| JO3178B1 (ar) | النموذج السادس البلوري الجديد من مركب الاغوميلاتين وطريقة تحضيره وتحضير المركبات الصيدلانية المحتوية عليه | |
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| ATE485292T1 (de) | Neue kristalline form von lamivudin | |
| HRP20120700T1 (hr) | SOLI SPOJEVA INHIBITORA HIV-a | |
| GB2605894A (en) | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt | |
| JO2684B1 (en) | Quinoline antibacterial derivatives | |
| RU2007136782A (ru) | Ингибирующие вич 2-(4-цианофенил)-6-гидроксиламинопиримидины | |
| IL266097B (en) | Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine | |
| WO2014014794A3 (fr) | Antagonistes des récepteurs aux minéralocorticoïdes | |
| EA202190036A1 (ru) | Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение | |
| MX2019008116A (es) | Proceso para la preparacion de compuestos de 5-amino-6h-tiazolo[4, 5-d]pirimidina-2,7-diona 3-sustituidos. | |
| MX2011012068A (es) | Nucleosidos 2'-fluoro arabino y su utilizaicon. | |
| HK1137431A1 (en) | Antibacterial quinoline derivatives | |
| WO2008106125A3 (fr) | Antagonistes du récepteur alpha 1a-adrénergique |